Genetic Cancer Risk in the Young (RisC) study

The RisC study is trying to understand more about the genetic variants that contribute to inherited cancers – understanding that is crucial for both cancer patients and their families. We trust that this knowledge will lead to more personalised cancer treatments that result in better outcomes, improved cancer screening, increased options for reducing cancer risks and more fully informed lifestyle and reproductive decisions. The study also aims to assess the health-related costs.

Patients (aged 16+ years) must have a histologically confirmed cancer and have:

• One cancer diagnosis ≤ 40 years of age, or
• Two cancer diagnoses ≤ 50 years of age, or
• Multiple primary cancer diagnoses at any age (excluding BCC)

• Discussing the study with the RisC team (via telephone or face-to-face)
• Consenting to access of samples held by your pathology centres
• Consenting to access to medical and similar records
• Providing a blood sample
• Supplying family history information
• Completing questionnaires
• Consenting to biobanking (optional)
• Consenting to access to Medicare/PBS data (optional)